enGene Holdings Inc
Research enGene Holdings Inc (ENGN) on Bullrun: market cap USD 119.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerENGN
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 119.24M
- Financial periodFY2025
- Net income-USD 117.30M
- Free cash flow-USD 100.72M
Valuation Snapshot
latest market cap is USD 119.24M.
About enGene Holdings Inc
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.
Frequently asked questions
What is enGene Holdings Inc's market cap?
enGene Holdings Inc's market capitalization is USD 119.24M.
What does enGene Holdings Inc do?
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.